130599-34-7

Usage

Uses

Used in Medicinal Chemistry:
5-(4-TRIFLUOROMETHYL-PHENYL)-2H-PYRAZOL-3-YLAMINE is used as a building block for the synthesis and development of more complex organic compounds. Its unique structure and properties make it a valuable component in creating new pharmaceuticals and therapeutic agents.
Used in Research and Development:
5-(4-TRIFLUOROMETHYL-PHENYL)-2H-PYRAZOL-3-YLAMINE is used as a research compound for studying its chemical properties, reactivity, and potential applications in various fields, including drug discovery and synthesis.

InChI:InChI=1S/C10H8F3N3/c11-10(12,13)7-3-1-6(2-4-7)8-5-9(14)16-15-8/h1-5H,(H3,14,15,16)

Upstream product

• 2967-66-0 methyl 4-(trifluoromethyl)benzoate 
• 71682-94-5 ω-cyano-4-trifluoromethylacetophenone 

Downstream Products

• 1452831-77-4 methyl 5-cyano-6,7-dihydro-6-oxo-3-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 
• 1141402-00-7 N-(3-(4-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)-2-mercaptoacetamide 
• 1040719-01-4 5-piperidin-1-yl-pentanoic acid [3-(4-trifluoromethylphenyl)-1H-pyrazol-5-yl]amide 
• 1374979-28-8 C₁₅H₁₅BrF₃N₃O 
• 1221129-35-6 5-hydroxy-6-phenyl-2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-7(6H)-one 
• 1448466-46-3 1,3-dihydro-7-(4-trifluoromethylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
• 1448466-61-2 1,3-dihydro-7-(4-trifluoromethylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one 
• 1040724-17-1 3-amino-5-(4-trifluoromethyl-phenyl)-pyrazole-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Polysubstituted heterocyclic derivative, preparation method thereof and application of polysubstituted heterocyclic derivative in medicine

The invention provides a polysubstituted heterocyclic derivative, a preparation method thereof and application of the polysubstituted heterocyclic derivative in medicine, and belongs to the technical field of medicinal chemistry. The polysubstituted heterocyclic derivative is a compound shown in a general formula I or II, a pharmaceutically acceptable salt or a solvate of the compound, and the compound can inhibit mRNA demethylase on the protease level and is used for treating diseases related to mRNA demethylase functions.

Unexpected reaction course of 3-Amino-5-aryl-1H-pyrazoles with dialkyl dicyanofumarates

On treatment of 3-amino-5-aryl-1H-pyrazoles 1 with dialkyl dicyanofumarates (=(E)-but-2-enedioates) 4 in boiling 1,2-dichloroethane, two competitive reactions occurred leading to 3-aryl-5-cyano-6,7-dihydro-6-oxo-1H-pyrazolo[3,4- b]pyridine-4-carboxylates

Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H- pyrazol-3-yl] amide (SEN15924, WAY-361789)

Alpha-7 nicotinic acetylcholine receptors (α7 nAChR) are implicated in the modulation of many cognitive functions such as attention, working memory, and episodic memory. For this reason, α7 nAChR agonists represent promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort, around our previously reported chemical series, permitted the discovery of a novel class of α7 nAChR agonists with improved selectivity, in particular against the α3 receptor subtype and better ADME profile. The exploration of this series led to the identification of 5-(4-acetyl[1,4] diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (25, SEN15924, WAY-361789), a novel, full agonist of the α7 nAChR that was evaluated in vitro and in vivo. Compound 25 proved to be potent and selective, and it demonstrated a fair pharmacokinetic profile accompanied by efficacy in rodent behavioral cognition models (novel object recognition and auditory sensory gating).

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS

The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can a

Botulinum neurotoxin serotype A inhibitors: Small-molecule mercaptoacetamide analogs

Botulinum neurotoxin elicits its paralytic activity through a zinc-dependant metalloprotease that cleaves proteins involved in neurotransmitter release. Currently, no drugs are available to reverse the effects of botulinum intoxication. Herein we report the design of a novel series of mercaptoacetamide small-molecule inhibitors active against botulinum neurotoxin serotype A. These analogs show low micromolar inhibitory activity against the isolated enzyme. Structure-activity relationship studies for a series of mercaptoacetamide analogs of 5-amino-3-phenylpyrazole reveal components essential for potent inhibitory activity.

NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.